Skip to main content
Premium Trial:

Request an Annual Quote

GNS Pens Cancer Rx-Dx-Development Alliance With Moffitt Subsidiary M2Gen

NEW YORK (GenomeWeb News) — Gene Network Sciences said today that it will use its REFSTM software in an alliance with H. Lee Moffitt Cancer Center subsidiary M2Gen to develop cancer diagnostics and therapeutics
GNS will use REFSTM, which stands for reverse engineering and forward simulation, to reverse-engineer computer models from de-identified tumor molecular profiling data provided by Moffitt.
Researchers will use the models to identify genes that cause cancer progression, and the relationships between those genes and endpoints such as recurrence and survival.
The parties will “work together to validate the discoveries and will work with strategic partners to rapidly bring the diagnostics to market,” GNS said in a statement.
Financial terms of the agreement were not disclosed.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.